Skip to main content
Premium Trial:

Request an Annual Quote

Metamark Secures Medicare Coverage for ProMark Prostate Cancer Test

NEW YORK (GenomeWeb) – Metamark Genetics said today that it has received Medicare coverage for ProMark, its proteomic test for prognosing early-stage prostate cancer.

Medicare Administrative Contractor Palmetto GBA issued a final local coverage decision for the test effective Oct. 10, 2016.

ProMark is a tool for identifying prostate cancer patients with likely non-aggressive forms of the disease that can be treated without surgery or radiation therapy. The test is intended for use in patients with biopsy Gleason Scores of 3+3 and 3+4.

"This is a tremendous step for ProMark, opening the door for greater access to essential, decision-making information for prostate cancer patients and their physicians, and enabling more informed and personalized treatment decisions," ProMark President and CEO Jerry Williamson said in a statement.